Published in Vaccine Weekly, June 8th, 2005
Revenues for the quarter ended March 31, 2005, totaled $2.6 million compared to revenues of $1.7 million for the same period in 2004. Revenues primarily reflect funding from government grants and contracts and payments received by the company for contract work performed for our joint venture with Cytogen Corporation, the PSMA Development company LLC.
The company's expenses for the first quarter of 2005 were $15.9 million, compared to $12.2 million for the first quarter of 2004. The primary reason for the increase was additional spending...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly